Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Operating margin-220.1%-15.6pp-204.5%+191,778pp-191,982.5%+475,672pp-667,654.5%+216,372pp-884,026.1%-376,348pp
Returns
Return on invested capital-51.1%-10.3pp-40.9%+22.0pp-62.9%-6.4pp-56.5%+1.6pp-58.2%+23.6pp
Efficiency
Asset turnover0.2×0.0×0.2×+0.2×0.0×0.0×
Liquidity
Current ratio9.3×-0.1×9.4×+1.0×8.4×-0.3×8.7×-3.6×12.4×-2.6×
Leverage
Debt-to-equity0.0×0.0×0.1×0.0×0.1×0.0×0.1×0.0×
Per Share
Book value per share$6.64-24.0%$8.73+32.8%$6.57-12.6%$7.53-10.7%$8.43-11.0%
Valuation
Market capitalization$602.22M+215%$428.51M+5.6%$405.84M+119%$185.3M+23.9%$149.56M-41.9%
Price / sales6.8×-8,306×-3,377×3,382×-2,233×5,615.1×-887×6,502.5×-457×
Price / book1.3×+0.9×0.8×-0.3×1.1×+0.7×0.4×+0.1×0.3×-0.2×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do 4D Molecular Therapeutics's ratios come from?
Every ratio is computed from 4D Molecular Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.